ArticleJournal of veterinary internal medicine2026
Neurologic improvement and tumor shrinkage after radiotherapy in dogs with imaging-based intracranial neoplasia.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTraditional measures of treatment success for radiotherapy in dogs with intracranial neoplasia include progression-free and overall survival time. Although important, these measures do not reflect neurologic function. HYPOTHESIS/
objectivesAssess tumor shrinkage by follow-up imaging and outcome using 2 neurodisability scoring systems-1 validated and 1 simplified. ANIMALS: One hundred six dogs with imaging-diagnosed intracranial tumors treated with 10-fraction definitive-intent radiotherapy.
methodsData were collected from 2 randomized trials. Neurologic function was prospectively assessed using a validated score, and a retrospective simplified score was added. Imaging was recommended every 6 months or upon clinical decline.
resultsDiagnoses included extraparenchymal tumors (45.3%), intraparenchymal tumors (35.8%), and pituitary tumors (18.9%). Median follow-up was 581 days. The neurodisability score improved significantly before radiotherapy (median 1.0, P = .04) because of medical management, and again during treatment (median 0.0, P < .01). At peak response, 76% of dogs had no or only mild neurologic deficits. Tumor volume significantly decreased at 6 and 12 months (P < .01): median shrinkage at 6 months was -39% (extraparenchymal tumors), -83% (intraparenchymal tumors), and -47% (pituitary tumors). A moderate correlation between tumor reduction and neurodisability score was seen only at 6 months (r = 0.395, P = .002). Results were consistent across protocols. CONCLUSIONS AND CLINICAL IMPORTANCE: Radiotherapy led to lasting neurologic improvement and substantial tumor reduction. Neurologic function did not always correlate with tumor volume shrinkage, emphasizing the importance of incorporating and prioritizing neurologists' functional assessments in posttreatment evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.